drugset
drugset / Trial / NCT00224822

The Effects of Aripiprazole on Patients With Metabolic Syndrome

NCT00224822 ↗

Phase 4 Completed 27 enrolled New Mexico VA Healthcare System Bristol-Myers Squibb · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary goal of this study is to assess the effect of aripiprazole on patients who developed metabolic syndrome while taking other second generation antipsychotic medications.

Timeline

Start
2004-03
Primary completion
—
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified — —

Indications

bipolar disorder metabolic syndrome X schizoaffective disorder schizophrenia